Immunostimulatory combinations
Assignees3M Innovative Properties Company, Trustees of Dartmouth College
InventorsRandolph J. Noelle, Cory L. Ahonen, Ross M. Kedl
Life of this patent
Estimating the term…
Abstract
The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.
Claims77
An immunostimulatory composition suitable for administration to a human subject in need of immunotherapy comprising:
- (i) at least one Toll-Like Receptor (TLR) agonist which is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists;
- and
- (ii) at least one CD40 agonist that directly binds CD40;
- and
- (iii) a pharmaceutically acceptable carrier,
- wherein (i) and (ii) are each comprised in an amount such that, in combination with the other, are effective to produce a synergistic increase in a human subject in an immune response to an antigen upon administration to a human subject in need of immunotherapy.
An immunostimulatory composition suitable for administration to a human subject in need of immunotherapy comprising:
- (i) at least one Toll-Like Receptor (TLR) agonist;
- (ii) at least one 4-1BB agonist that directly binds 4-1BB;
- and
- (iii) a pharmaceutically acceptable carrier,
- wherein (i) and (ii) are each comprised in an amount such that, in combination with the other, are effective to produce a synergistic increase in a human subject in an immune response to an antigen upon administration to a human subject in need of immunotherapy.
A vaccine composition suitable for administration to a human subject in need thereof comprising:
- (i) at least one TLR agonist which is selected from the group consisting of TLR 1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists;
- (ii) at least one CD40 agonist that directly binds CD40;
- (iii) at least one antigen;
- and
- (iv) at least one pharmaceutically acceptable carrier;
- wherein (i) and (ii) are each comprised in an amount that, in combination with the other, are effective for inducing a synergistic immune response to the (iii) antigen in a human subject upon administration of the vaccine.
A vaccine composition suitable for administration to a human subject in need thereof comprising:
- (i) at least one TLR agonist;
- (ii) at least one 4-1BB agonist that directly binds 4-1BB;
- (iii) at least one antigen;
- and
- (iv) at least one pharmaceutically acceptable carrier;
- wherein (i) and (ii) are each comprised in an amount that, in combination with the other, are effective for inducing a synergistic immune response to the (iii) antigen in a human subject upon administration of the vaccine.
Dependencies are inferred from the claim text.